The store will not work correctly when cookies are disabled.
4-[(3-Bromobenzyl)oxy]-2-fluorobenzamide
ID: ALA5186481
PubChem CID: 168279249
Max Phase: Preclinical
Molecular Formula: C14H11BrFNO2
Molecular Weight: 324.15
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: NC(=O)c1ccc(OCc2cccc(Br)c2)cc1F
Standard InChI: InChI=1S/C14H11BrFNO2/c15-10-3-1-2-9(6-10)8-19-11-4-5-12(14(17)18)13(16)7-11/h1-7H,8H2,(H2,17,18)
Standard InChI Key: WBKKGOVCGYZDCH-UHFFFAOYSA-N
Molfile:
RDKit 2D
19 20 0 0 0 0 0 0 0 0999 V2000
-1.7875 0.4130 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0729 0.8253 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3611 0.4134 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3611 -0.4117 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0711 -0.8235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7875 -0.4154 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0711 -1.6487 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.3565 -2.0613 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3580 -1.6487 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0729 1.6505 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7876 2.0631 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.3583 2.0631 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.3583 -0.8235 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0712 -0.4128 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7860 -0.8255 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.7876 -1.6466 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0758 -2.0631 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0712 0.4124 0.0000 Br 0 0 0 0 0 0 0 0 0 0 0 0
0.3535 0.8260 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
4 3 2 0
5 4 1 0
6 5 2 0
1 6 1 0
5 7 1 0
7 8 1 0
8 9 1 0
2 10 1 0
10 11 2 0
10 12 1 0
13 9 2 0
14 13 1 0
15 14 2 0
16 15 1 0
17 16 2 0
9 17 1 0
14 18 1 0
3 19 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 324.15 | Molecular Weight (Monoisotopic): 322.9957 | AlogP: 3.27 | #Rotatable Bonds: 4 |
Polar Surface Area: 52.32 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 3 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 12.89 | CX Basic pKa: ┄ | CX LogP: 3.30 | CX LogD: 3.30 |
Aromatic Rings: 2 | Heavy Atoms: 19 | QED Weighted: 0.94 | Np Likeness Score: -1.45 |
References
1. Nizi MG, Maksimainen MM, Murthy S, Massari S, Alaviuhkola J, Lippok BE, Sowa ST, Galera-Prat A, Prunskaite-Hyyryläinen R, Lüscher B, Korn P, Lehtiö L, Tabarrini O.. (2022) Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15., 237 [PMID:35500474] [10.1016/j.ejmech.2022.114362] |